Therefore, we examined LARC patients, in vitro models of CRC, and an in vivo model of CRC in which the tumors had different XRCC2 status to assess the radiosensitizing effect of olaparib, a drug approved for the treatment of several cancers with BRCA mutations. Here, XRCC2 is linked to colorectal carcinoma.